Acquisition to strengthen key pillar of BioNTech's oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancersWith the closing of the transa ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of Biotheus ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

Investing.com -- Moderna (NASDAQ: NASDAQ: MRNA) stock declined 4.9% and BioNTech SE (NASDAQ: NASDAQ: BNTX) shares fell 1.5% ...

Atomi Financial Group Inc. raised its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 6.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional ...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs ...

BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investing.com's Fair Value model demonstrated its effectiveness once again, identifying a significant opportunity in BioNTech SE (NASDAQ:BNTX) that resulted in a remarkable 51% return over just six ...